SCHEMBL20810163

SCHEMBL20810163

COc1ccc(-c2cc(COC(=O)c3cccnc3)on2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ MAPT P10636 5/20 0.54
▸ TDP1 Q9NUW8 4/20 0.54
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ NPC1 O15118 3/20 0.54
▸ RAB9A P51151 3/20 0.54
▸ KMT2A Q03164 3/20 0.53
▸ MAPK1 P28482 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ ALDH1A1 P00352 4/20 0.49
▸ LMNA P02545 4/20 0.49
▸ POLB P06746 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ CYP3A4 P08684 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20810166 0.90 ALDH1A1 (0.53) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810154 0.89 TDP1 (0.54) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810152 0.88 TDP1 (0.53) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810037 0.88 TDP1 (0.59) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810155 0.87 KMT2A (0.54) SMN1; SMN2MAPTTDP1L3MBTL1RAB9A
SCHEMBL20810153 0.87 TDP1 (0.54) MAPTTDP1L3MBTL1NPC1RAB9A
SCHEMBL20810161 0.86 TDP1 (0.58) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810149 0.84 TDP1 (0.51) SMN1; SMN2MAPTTDP1L3MBTL1KMT2A
SCHEMBL20810165 0.82 TDP1 (0.51) SMN1; SMN2MAPTTDP1L3MBTL1NPC1
SCHEMBL20810167 0.82 SMN1; SMN2 (0.65) SMN1; SMN2MAPTTDP1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF XIAMEN INSTITUTE OF RARE EARTH MATERIALS (CN) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077777-A1 NICOTINIC ACID DERIVATIVES, THEIR PREPARATION AND THE USE THEREOF H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCAR3, NAPRT SMN1; SMN2 2249/4885MAPT 4604/4885TDP1 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback